 ORIC Pharmaceuticals Inc NASDAQ: ORIC announced initial data from Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. Data were presented at AACR-NCI-EORTC. 